The presence of congenital antithrombin deficiency has been consistently shown to predispose patients to venous thrombosis. We have utilized the prothrombin fragment F1+2 radioimmunoassay to quantitate factor Xa activity in the blood of 22 asymptomatic individuals with this clinical disorder not receiving antithrombotic therapy. The mean level of F1+2 was significantly elevated in these patients as compared to normal controls (3.91 vs. 1.97 nM, P < 0.001). The metabolic behavior of 131I-F,+2 was found to be similar in antithrombin-deficient subjects and normal individuals. The hemostatic system hyperactivity as measured by the F1+2 assay could be specifically corrected by raising the plasma antithrombin levels of the above asymptomatic individuals into the normal range. This study provides the first demonstration that the prethrombotic state can be biochemically defined as an imbalance between the production and inhibition of factor Xa enzymatic activity within the human circulation. It is known that antithrombin and a1-proteinase inhibitor (PI) are the major inhibitors of factor Xa in human plasma in the absence of heparin. To further evaluate the mechanism by which antithrombin functions as an inhibitor of factor Xa in humans, we studied five patients who exhibited severe congenital deficiencies of a,-PI. Our results indicated that the plasma of these subjects showed virtually identical decreases in plasma antifactor Xa activity in the absence of heparin when compared to antithrombin-deficient individuals, but the plasma F1+2 levels in the a,-PI deficient population were not significantly different than normal. This data suggests that a,-PI does not function as a major inhibitor of factor Xa in vivo, and that a tonically active heparin-dependent mechanism exists in humans for accelerating the neutralization of this enzyme by antithrombin.
Introduction
The conversion of prothrombin to thrombin is the central event in the coagulation of blood. This reaction takes place at an appreciable rate under physiologic conditions only in the presence of factor Xa, factor Va, calcium ions, and platelets. During this process, the amino terminus of the prothrombin molecule is released as the inactive F,+2 fragment in conjunction with the generation of thrombin. Once evolved, this serine protease is able to cleave two pairs of peptides from fibrinogen, fibrinopeptides A and B, which permits the resulting fibrin to polymerize into an insoluble clot. Alternatively, thrombin can be inhibited by its natural antagonist, antithrombin, via the formation of a stable enzyme-inhibitor complex. Although other plasma proteins are able to inactivate this enzyme, antithrombin is the inhibitor of primary physiologic importance (1) (2) (3) . Other serine proteases of the coagulation system that are neutralized by this inhibitor include factors IXa, Xa, XIa, and XIIa (4) (5) (6) (7) . Each of these enzyme-inhibitor interactions is accelerated by heparin (1, (4) (5) (6) (7) .
We have developed a sensitive and specific radioimmunoassay (RIA)' for F,+2 which measures the in vivo cleavage of the prothrombin molecule by factor Xa (8, 9 ). Nossel and co-workers (10-12) have established a similar assay for fibrinopeptide A (FPA), which quantitates the in vivo cleavage of fibrinogen by thrombin. For the work reported here, we have utilized these immunochemical techniques to demonstrate that substantial elevations in factor Xa activity, but not thrombin activity, regularly occur in the blood of asymptomatic individuals with congenital antithrombin deficiency, an inherited disorder known to be highly correlated with the subsequent development of thrombosis. This biochemical abnormality could be specifically corrected by raising the plasma antithrombin levels of the above asymptomatic individuals into the normal range. We have also compared our findings in this population with those in a cohort of patients with low levels of a,-proteinase inhibitor (PI), a plasma protein which makes a substantial contribution to in vitro plasma antifactor Xa activity in the absence of heparin. Based upon the accumulated data, we suggest that a tonically active heparin-dependent mechanism exists within the vascular system of humans for accelerating the neutralization of factor Xa by antithrombin. Our studies also demonstrate that the prethrombotic state can be biochemically defined by utilizing techniques, such as the F,+2 assay, that quantitate the in vivo activity of the coagulation mechanism in the circulation.
Methods
Column chromatographic materials and reagents. DEAE-cellulose and dry hydroxylapatite were purchased from Bio-Rad Laboratories, Richmond, CA. Sephadex G-25 and Heparin-Sepharose CL-6B were obtained from Pharmacia Fine Chemicals, Piscataway, NJ. Heparin (Panheprin) was bought from Abbott Laboratories, North Chicago, IL. Proteins. Bovine serum albumin was purchased from Sigma Chemical Co., St. Louis, MO. Human prothrombin was prepared by the method of Shapiro et al. (13) with minor modifications as described in a prior communication from our laboratory (8) . Human factor Xa, human antithrombin, human thrombin, and human F1+2 were purified by techniques established in our laboratory (8, 14, 15) . Protein concentrations were determined from the absorbance of protein solutions at 280 nm. The molar extinction coefficients for human prothrombin, human factor Xa, human antithrombin, human thrombin, and human F1+2 were assumed to be 13.6, 11.6, 6.5, 16.2, and 12.9, respectively (8, 16) .
Collection and processing of blood samples. Venipunctures were performed atraumatically with 19-or 21-gauge butterfly infusion sets using a two-syringe technique. Blood samples were drawn into plastic syringes preloaded with the appropriate solutions as described below. These included: (a) For all functional assays and immunologic measurements of antithrombin, a,-PI, and prothrombin, 3.8% (wt/vol) sodium citrate was employed; the ratio of anticoagulant to blood used was 0.1:0.9 (vol/vol). (b) "F1+2 anticoagulant": citric acid 7.3 mg/ml, sodium citrate 22 mg/ml, dextrose 24.5 mg/ml, EDTA 2.234 mg/ml, adenosine 1.602 mg/ml, and heparin 25 U/ml. The ratio of anticoagulant to blood employed was 0.2:1.0 (vol/vol). (c) "FPA anticoagulant": This preparation was provided by Mallinckrodt, Inc., St. Louis, MO. The ratio of anticoagulant to blood used was 0.1:0.9 (vol/vol). After collection of blood samples, plasma fractions were obtained by centrifugation at 4VC for 15 min at 1,600 g and stored at -80'C before use.
Normal ranges for antithrombin, a,-PI, F,+2, and FPA were derived from data on control subjects. This population consisted of healthy individuals who gave a negative history for bleeding as well as thrombosis, and were not taking any medications at the time of sample collection. A normal plasma pool was constructed by pooling equal volumes of plasma from these control subjects.
Coagulation studies. Routine coagulation studies including prothrombin time and activated partial thromboplastin time were performed by standard laboratory methods (17) .
Immunoassays. The plasma concentrations of antithrombin, prothrombin, and F1+2 were determined by double antibody RIA as described in earlier reports from our laboratory (9, 18) . The plasma levels of FPA were established by RIA utilizing a kit provided by Mallinckrodt, Inc. a,-PI levels were measured employing a nephelometric method (19) .
Plasma antithrombin functional assays. An amidolytic assay for heparin cofactor activity utilizing the chromogenic substrate Tos-GlyPro-Arg-pNA (Chromozym TH, Boehringer Mannheim, Indianapolis, IN) was employed as previously described (20) , except that the heparin concentration in the diluent buffer was reduced from 3 to 0.5 U/ml. A ratio of plasma to diluent buffer of 1:59 (vol/vol) was defined as 100% activity. Normal plasma dilutions and samples were each run in duplicate. The activity of test samples was obtained by comparison to a standard curve constructed from dilutions of a normal plasma pool and their respective absorbance readings (r = -0.99). The interassay standard deviation for a given plasma sample was 2.9% (30 determinations). Plasma antifactor Xa functional assays. Plasma antifactor Xa activity was measured in the presence and absence of heparin by employing amidolytic methods similar to those described by Odegard et al. (21) . Because human factor Xa and the chromogenic substrate MeO-CO-D-cyclohexyl-glycyl-Gly-Arg-pNA.AcOH (Spectrozyme FXa, American Diagnostica, Greenwich, CT) were utilized in our assay system, it proved necessary to make several modifications in the above protocols as outlined below.
Assays of plasma antifactor Xa activity in the presence of heparin were performed by preparing 1/30 to 1/80 dilutions of normal plasma in buffer (0.05 M Tris-HCI, 0.18 M NaCl, 0.0075 M Na2EDTA, pH 8.4, containing 3 U/ml heparin). A ratio of plasma to diluent buffer of 1:49 (vol/vol) was defined as 100% activity. Test samples were diluted appropriately with buffer, as judged by their probable antifactor Xa activity. Exactly 200 ul of standard or sample was then transferred into each of two test tubes and prewarmed in a water bath at 370C for 2 min. A volume of 100 ul of factor Xa (6 #g/ml in buffer) was then admixed, and a stopwatch was started. After 10 min of incubation, 50 microliters of substrate (I mM MeO-CO-D-cyclohexyl-glycyl-GlyArg-pNA.AcOH, 0.3 mg/ml polybrene) was added to each tube. Exactly 10 min later, 200 Ml of glacial acetic acid was added and the contents were thoroughly mixed. Normal plasma dilutions and samples were each run in duplicate. Absorbances were read at 405 nm against a blank containing 200 ul of the corresponding standard plasma dilution or sample, 150 Ml of buffer, and 200 ul of glacial acetic acid. The antifactor Xa activity of test samples was obtained by comparison to a standard curve constructed from the known normal plasma dilutions and their respective absorbance readings (r = -0.98). The interassay standard deviation for a given plasma sample was 4.8% (five determinations).
Assays of plasma antifactor Xa activity in the absence of heparin were performed by preparing 1/5 to 1/20 dilutions of normal plasma in buffer (0.05 M Tris-HCI, 0.17 M NaCl, 0.0073 M Na2EDTA, pH 8.4 containing polybrene 0.05 mg/ml). A ratio of plasma to diluent buffer of 1:9 (vol/vol) was defined as 100% activity. Test samples were diluted appropriately with buffer, as judged by their probable antifactor Xa activity. Factor Xa was diluted to a concentration of 4 Mg/ml in buffer. The assay was then carried out in a manner entirely analogous to that described for the assay in the presence of heparin except that the final incubation lasted only 8 min. The activity of test samples was obtained by comparison to a standard curve constructed from the known plasma dilutions and their respective absorbance readings (r = -0.97). The interassay standard deviation for a given plasma sample was 1.5% (five determinations).
F,+2 preparation for turnover studies. Human F1+2 was purified from 2 liters of fresh frozen plasma obtained from four healthy donors who had been carefully screened for hepatitis and acquired immune deficiency syndrome. The plasma was allowed to warm to 24°C and clotting was initiated by the addition of CaCI2 (final concentration 32.4 mM). After 90 min of incubation, the clot was removed, heparin (final concentration I U/ml) was added, and the suspension was stirred for an additional 5 min. Subsequently, F1+2 was isolated from the sera by DEAE-cellulose batch adsorption-elution and hydroxylapatite chromatography as described by Aronson et al. (22) . Examination of a series of fractions eluted from hydroxylapatite with a potassium phosphate concentration of 0.35-0.45 M, revealed that >90% of the resultant material was F1+2 as judged by the sodium dodecyl sulfate (SDS) gel electrophoretic technique of Laemmli (23) . In order to remove minor higher and lower molecular weight components which migrated at rates similar to those of prothrombin and F. respectively, 2 mg of F1+2 in 15 ml of 0.02 M Tris-HCI, 0.05 M NaCI, pH 7.5, was filtered at 20 ml/h through a column of heparin-Sepharose (0.8 X 13 cm) equilibrated with the same buffer. The heparin-Sepharose was sterilized during its preparation, and had not previously been used for any other purpose. The matrix was then washed with the above buffer. This procedure was conducted at 4°C. The recovery of F1+2 by absorbance measurements averaged 90% of the total amount applied to the column. Analysis of the resultant product by SDS gel electrophoresis confirmed that the minor contaminating species had been eliminated. The overall yield from 2 liters of plasma averaged -3.6 mg. All buffers were made in sterile, pyrogen-free water, and all glassware had been autoclaved prior to use.
'31I-F,+2 preparation and turnover studies. Radiolabeling of antigen was accomplished by the method of Greenwood et al. (24) utilizing 15 Mg of F1+2 and 0.6 mCi of carrier free Na'3'I (New England Nuclear, Boston, MA Analysis of data. Estimation of relative immunoreactivity, computation of the slopes of the dose-response curves, as well as determinations of the various associated indices were obtained by a leastsquares fit of the RIA results to a "four-parameter" model as described by Rodbard (29, 30) . Statistical analyses of data were conducted by standard techniques (31) . In most instances, the means are provided with associated standard deviations.
Results
The hemostatic system activity in the blood of patients with congenital antithrombin deficiency was examined. Eight kindreds were available for study where at least two people in each family had previously experienced thrombotic events. The clinical histories and laboratory evaluation of several of these families (Table I; families II, III, and VIII) have been reported previously in the literature (18, 32, 33) . Seven of the pedigrees exhibited the "classical" antithrombin deficiency state which is caused by a reduced synthesis of biologically normal inhibitor molecules (34) . In these cases, both the immunologic and heparin cofactor activity of antithrombin were reduced to the same extent. Affected members of family VIII possessed the other major subtype of inherited antithrombin deficiency. This disorder is produced by a discrete molecular 22 antithrombin deficient subjects derived from these kindreds were studied in detail (Table I ; Fig. 1 ). The median age of this cohort on the date of the initial evaluation was 22 yr. All of these individuals were asymptomatic and none were receiving heparin or coumarin derivatives. Only seven ofthese patients had a prior history of an overt thrombotic episode. Routine coagulation studies including prothrombin time, activated partial thromboplastin time, and platelet count were within normal limits in this population. For comparison, we also provide data on 12 siblings of our antithrombin deficient patients who possessed normal antithrombin levels by immunologic and functional assay (Fig. 1) (Fig. 2) ; '31I-F1+2 plasma radioactivity and F1+2 plasma immunoreactivity can each be described by a two-exponential curve, CIeCr" + C2er'2 (35). The fractional breakdown rate, kB, was calculated from [C1/r, + C2/r2]f' (36) . The values for C1, r,, C2, r2, kB in the radioactive and immunologic studies were 0.781, 0.265, 0.214, 9.75, 0.337, and 0.852, 0.334, 0.161, 9.21, 0.389, respectively. Similar results were obtained in a second animal. These investigations revealed that iodination did not affect the metabolic behavior of the native F1+2.
Clearance studies with '31I-F1+2 were then undertaken in antithrombin deficient subjects and normal individuals. The results of turnover studies carried out in patients 1-1 and V-2 as well as two normal male controls are shown in Fig. 3 . The antithrombin-deficient patients selected for study each had plasma measurements of F1+2 that were >4 nM, whereas the normal individuals both had levels of this fragment that were under 2 nM. No substantial differences were noted in the plasma radioactivity measurements of the four individuals. This impression was confirmed by fitting the data obtained during the first 6 h to a two-exponential curve which allowed us to compute several metabolic parameters (Table II) . In addition, the number of non-trichloroacetic acid-precipitable counts in the plasma never exceeded 10% of the total amount present during this period. Whole body radioactivity measurements revealed similar patterns in the four patients, and the mean number of residual counts remaining in the subjects at 30 h after the initiation of these studies was 23% of the total infused dose. The amount of radioactivity excreted in the urine during the first 24 declined from their peak value after infusion, and started to rise towards the preinfusion value only when the plasma concentration of the inhibitor dropped below -70%o of normal. No significant change in the level of FPA was noted in either individual throughout the duration of the study. Finally, the infused antithrombin was found to have a half-life within the circulation of -48 h which is similar to that obtained in metabolic clearance studies of the radiolabeled protein in humans (34, 37) .
It is known that a,-PI contributes -significantly to the in vitro neutralization of factor Xa by human plasma in the absence of heparin. Gitel et al. (38) Numerous investigators have postulated that a hypercoagulable state exists in humans for a prolonged period of time before the development of thrombotic episodes (39) . This hypothesis is supported to some extent by various clinical trials in which antiplatelet and anticoagulant medications have been shown to provide some protection against the recurrence of arterial and venous thrombotic disease (40-43). However, a clear biochemical definition of the prethrombotic state has to date proved elusive because of the complex nature of the hemostatic mechanism, the lack of reliable techniques for monitoring pertinent changes in blood coagulability, and the almost exclusive focus upon complicated multifactorial vascular disorders.
Based upon recent advances in our knowledge of the biochemistry of the coagulation system, a series of highly specific immunoassays have been designed that monitor the in vivo activities of various steps of the hemostatic mechanism.
In this communication, we have utilized the F1+2 and FPA RIAs to characterize the extent of hemostatic mechanism activity in the blood of asymptomatic individuals with congenital antithrombin deficiency. This disorder represents a relatively simple, inherited hypercoagulable state, which is consistently linked with venous and occasionally arterial thrombosis. Indeed, it has been estimated that at least 55% of the individuals with congenital reductions in the levels of this protease inhibitor experience one or more thrombotic events (44) . Our studies were carried out in an antithrombin-deficient population that contained a large percentage of young individuals who had not previously sustained any thrombotic events. The data demonstrate that asymptomatic patients with this disorder usually exhibit increased concentrations of F1+2 and that the levels of this species are quite stable over a prolonged period of time within the blood of a given individual. We have also shown that the metabolic behavior of F1+2 in antithrombindeficient patients with high concentrations of this marker are similar to that observed in a normal control population. Therefore, these results allow us to conclude that most individuals with congenital reductions of the protease inhibitor have excessive plasma factor Xa activity for several years before the development of overt vascular disease.
The F1+2 turnover studies also permit us to assess quantitatively the extent to which physiologic or pathologic activation of the coagulation mechanism contributes to the catabolism of prothrombin in the circulation of humans. In a steady state, the rate of F1+2 production, F, must equal the breakdown rate, B. Under these conditions: F (nanomoles/hour) = B (nanomoles/hour) = kB X V X C, where V is the plasma volume of the patient, kB is the fraction of plasma F1+2 broken down per hour in a steady state, and C is the ambient F1+2 concentration (34) . Using this equation, we calculate that a normal 70-kg individual (plasma volume -2.8 liters, kB 0.365) with an ambient F1+2 value of 2 nM would generate 2.04 nmol/h of this fragment. Shapiro and Martinez (45) have previously determined that the rate of catabolism of prothrombin in a normal 70-kg subject is 0.104 gmol/h. Thus, the rate of production of F1+2 is equivalent to only 2% of the normal daily catabolism of prothrombin on a molar basis. It is also clear from the above relationships that an antithrombindeficient patient of 70-kg (plasma volume -2.8 liters, kB -0.365) with an ambient F1+2 level of 4 nM would generate 4.08 nmol/h of this fragment which is twice that of the normal individual considered above. This rate of production of F1+2 is equivalent to 4% of the normal daily catabolism of prothrombin on a molar basis given that the rate of synthesis of this zymogen in an antithrombin-deficient patient is similar to that in the normal population (46) . These estimates confirm the supposition of Shapiro and Martinez (45) that the metabolism of prothrombin in normal and hypercoagulable states is predominantly controlled by general catabolic pathways, rather than by the conversion of zymogen to thrombin. Hence, measurements of prothrombin level or clearance of the labeled zymogen are unlikely to be of any value in defining the presence of the prethrombotic state in humans.
The infusion of purified concentrates of antithrombin into two individuals with a congenital deficiency of the protease inhibitor resulted in the normalization of the plasma levels of antithrombin and the concordant correction of hemostatic system hyperactivity as judged by the F1+2 assay. It is of particular interest to note that the elevated concentration of the activation fragment in patient IV-1 decreased at a rate which is consistent with that predicted from our metabolic studies of this marker once the plasma concentration of the 832 Bauer, Goodman, Kass, and Rosenberg protease inhibitor was raised to or above her normal value.
Thus, it is highly unlikely that the increased levels of F1+2 observed in this hypercoagulable population are produced during venipuncture because of the low ambient concentrations of antithrombin. Indeed, these data directly support the concept that factor Xa and perhaps thrombin are continuously generated within the vascular system of humans.
Marcum et al. (47) (48) (49) (50) Carlson and co-workers (51) have noted that metabolic turnover studies with radiolabeled antithrombin are consistent with a model in which 10-20% of the total pool of antithrombin is associated with a noncirculating vascular compartment which probably represents the heparinlike proteoglycans of the vessel wall. We believe that antithrombin bound to the vessel wall in an activated conformation constitutes the protease inhibitor population of major physiologic importance whereas the same protein free within the blood is of minimal functional relevance. Therefore, we speculate that antithrombin-deficient patients have an insufficient pool of activated protease inhibitor to adequately suppress factor Xa generated within the circulation thereby resulting in elevated F1+2 values. It is impossible at the present time to determine whether this increased action of factor Xa upon prothrombin observed in antithrombindeficient patients originates on the surface of platelets (52, 53 (63) (64) (65) (66) and VIIIa (63, 65, 67) . It has also been shown that protein S is able to enhance the binding of activated protein C to phospholipid-containing membranes and thereby accelerate the cleavage of the above activated cofactors (68, 69) . Therefore, activated protein C in concert with protein S is able to inhibit the factor Xa-factor Va-cell surface dependent conversion of prothrombin to thrombin as well as the concomitant liberation of F1+2 (70). We have recently observed that F1+2 levels are significantly elevated in nonanticoagulated asymptomatic patients from kindreds with congenital deficiencies of protein C (71) and protein S. These disorders are also highly correlated with an excessive incidence of thromboembolic disease and have clinical presentations similar to that of antithrombin deficiency (72-75). Thus, it seems possible that an excessively active protein C-thrombomodulin mechanism within antithrombin-deficient patients could lead to a normal level of F1+2 and the absence of a thrombotic tendency.
In this regard, it is critical to emphasize that most asymptomatic patients with antithrombin deficiency exhibit hemostatic system hyperactivity for prolonged periods of time as quantitated by the F1+2 assay and yet the documented occurrence of thrombotic complications within this population is episodic. A compilation of such vascular events in patients with congenital reductions of the protease inhibitor reveals that the first attack occurred in 58% of these patients in conjunction with a process known to trigger thrombosis, such as surgery, pregnancy, delivery, trauma, etc., and was spontaneous in only 42% of this population (44) . The biochemical processes which are responsible for the conversion of this hypercoagulable state into an actively thrombotic one are poorly understood at the present time. One might surmise that a variety of events could acutely depress the effective functioning of the endogenous heparin-antithrombin or protein C-thrombomodulin mechanisms. These would include minor alterations in the plasma concentrations of antithrombin or protein C, transient reductions in the levels of heparinlike proteoglycans or thrombomodulin on the surface of endothelial cells, excessive liberation of the platelet inhibitors of these natural anticoagulant mechanisms such as platelet factor four (76), heparitinase (77) , or protein C antiactivator (78) . The acute dysfunction of the fibrinolytic system may also play an important role in thrombus formation (79) .
Despite our uncertainties about various aspects of the pathophysiology of antithrombin deficiency, it is clear that most patients with congenital reductions of the protease inhibitor constitute a population with a true prethrombotic state, i.e., they have excessive production of factor Xa enzymatic activity with insufficient generation of thrombin to convert significant amounts of fibrinogen to fibrin. It remains to be determined whether acute elevations in the concentrations of F1+2 will have predictive value in determining the subsequent development of a thrombotic event in antithrombin-deficient subjects. However, because increased levels of this marker are normalized by infusions of antithrombin concentrates in this population, we should be able to utilize our RIA in designing optimal therapeutic regimens for suppressing the hypercoagulable state in individuals with congenital deficiencies of the protease inhibitor. Finally, the ability of the F1+2 assay to define increased activity of the hemostatic system in a population with a simple inherited hypercoagulable disorder suggests that this immunochemical tool can be employed to improve our understanding of other more complex hypercoagulable states as well as to develop effective treatment strategies in these situations.
